Men and women benefit differently from immunotherapy
Dr. Anna D. Wagner discussed the importance of recognizing the importance of sex and gender as modifiers of health and disease. One presentation (Abstract 1041P) had assembled eight randomized trials in non-small cell lung cancer (NSCLC) including 5199 patients where immune check point inhibitors (ICIs) vs standard chemotherapy showed a significant benefit when analyzing overall survival (OS) for both men and women. When looking at progression-free-survival (PFS) however, only men obtained a benefit.
This stressed the need for reliable Precision Medicine tools. 2cureX is well under way in developing a immune-oncology IndiTreat test together with University Medical Center Hamburg-Eppendorf (UKE) in Hamburg.